A cell-permeable purine compound that acts as a high affinity AhR antagonist (IC
50 = 127 nM against 3 nM TCDD-induced luciferase reporter activity in HepG2 cultures), but not a panel of 61 kinases. AhR expression and function knockouts by shRNAs, CH-223191 (Cat. No.
182705), or SR1 treatment all result in enhanced and sustained CD34
+ population in long-term proliferating/expanding cultures of cord blood-derived HSCs (hematopoietic setem cells) in serum-free media containing Tpo (Cat. No.
605218), SCF (Cat. No.
569600), Flt3 Ligand (Cat. No.
343010), and IL-6 (Cat. No.
407652) in a reversible manner. SR1 is reactive toward human, monkey, and canine, but not rat or murine, species.